abstract: Members of the transforming growth factor-b (TGF-b) superfamily are likely to have major roles in the regulation of tissue and vascular remodelling in the corpus luteum (CL). There are four inhibitor-of-differentiation (ID1 -4) genes that are regulated by members of the TGF-b superfamily and are involved in the transcriptional regulation of cell growth and differentiation. We studied their expression, localization and regulation in dated human corpora lutea from across the luteal phase (n ¼ 22) and after human chorionic gonadotrophin (hCG) administration in vivo (n ¼ 5), and in luteinized granulosa cells (LGCs), using immunohistochemistry and quantitative RT -PCR. ID1 -4 can be localized to multiple cell types in the CL across the luteal phase. Endothelial cell ID3 (P , 0.05) and ID4 (P , 0.05) immunostaining intensities peak at the time of angiogenesis but overall ID1 (P , 0.05) and ID3 (P , 0.05) expression peaks at the time of luteolysis, and luteal ID3 expression is inhibited by hCG in vivo (P , 0.01). In LGC cultures in vitro, hCG had no effect on ID1, down-regulated ID3 (P , 0.001), and up-regulated ID2 (P , 0.001) and ID4 (P , 0.01). Bone morphogenic proteins (BMPs) had no effect on ID4 expression but up-regulated ID1 (P , 0.01 to P , 0.005). BMP up-regulation of ID2 (P , 0.05) was additive to the hCG up-regulation of ID2 expression (P , 0.001), while BMP cancelled out the down regulative effect of hCG on ID3 regulation. As well as documenting regulation patterns specific for ID1, ID2, ID3 and ID4, we have shown that IDs are located and differentially regulated in the human CL, suggesting a role in the transcriptional regulation of luteal cells during tissue and vascular remodelling.
Introduction
Although the corpus luteum (CL) is fundamental to human reproduction, we still do not fully understand how it functions at the molecular level. The formation of a CL involves marked angiogenesis, cell differentiation and dynamic tissue remodelling ). In the absence of a pregnancy, a fully functioning CL, which is the most active steroidogenic gland in the body, will regress within days (Stouffer et al., 1993) . Luteolysis involves vascular regression ), cell death (Stocco et al., 2007) , immune cell influx (Duncan et al., 1998a) and tissue remodelling (Duncan et al., 1998b, Curry and Osteen, 2003) such that it rapidly becomes a small avascular fibrous remnant.
In a conception cycle, exponentially increasing human chorionic gonadotrophin (hCG) from the conceptus rescues the CL from luteolysis to maintain its vascular (Wulff et al., 2001) , structural and functional integrity (Stouffer et al., 1993; Duncan, 2000) . As not all the effects of hCG are on cells expressing its receptor (LHCGR), locally produced paracrine molecules are crucially involved in the regulation of luteal structure and function . Members of the transforming growth factor-b (TGF-b) superfamily are likely to be key regulators of many of the disparate processes involved in luteal development, maintenance and regression (Knight and Glister, 2006) .
The inhibitor of differentiation (ID) proteins are a subfamily of dimeric basic helix -loop -helix (bHLH) transcription factors. There are four mammalian isoforms (ID1 -4), which act during embryogenesis and development to repress transcription of genes required for lineage commitment. This regulates both differentiation and entry into the cell cycle and promotes cell growth. Importantly, their expression can be regulated by members of the TGF-b superfamily, notably the bone morphogenic proteins (BMPs) and activin A. We have suggested that activin A is a key regulatory molecule involved in luteolysis in women (Myers et al., 2007) .
We have also previously shown that the IDs are differentially expressed during follicle development in the sheep in vivo, and in ovine granulosa cells in vitro their expression was stimulated by BMP6 and inhibited by activin A (Hogg et al., 2010) . This suggested a role for IDs in the physiological regulation of mammalian ovarian structure and function. We therefore hypothesized that the IDs are important transcriptional regulators involved in the tissue and vascular remodelling observed across the luteal phase in women.
We aimed to: (i) determine whether ID1 -4 are expressed in the human CL; (ii) assess whether they are differentially regulated across the luteal phase; (iii) investigate which cell types express ID1 -4 in human CL and whether there is differential localization across the luteal phase; (iv) determine whether their expression is regulated by hCG in vitro or in vivo; and (v) investigate whether BMPs and activin A differentially regulate ID1 -4 expression in human luteal steroidogenic cells.
Herein, we describe studies using well-characterized human CL collected across the luteal phase and after exogenous treatment with hCG in vivo to simulate maternal recognition of pregnancy and primary cultures of human luteinized granulosa cells (LGCs). We provide evidence that the ID genes are individually differentially regulated in luteal cells, suggesting their involvement in luteal tissue and vascular remodelling.
Materials and Methods

Reagents
Reagents were obtained from Sigma-Aldrich (Poole, Dorset, UK) unless otherwise specified. Insulin-Transferrin -Selenium-X (ITS) was obtained from Invitrogen Life Technologies, Inc. (Gaithersburg, MD, USA). Matrigel was a product of BD Biosciences (Bedford, MA). Bone morphogenetic protein (BMP)-2, -4 and -6 and activin A were obtained from R&D Systems (Abingdon, Oxon, UK).
Collection of human CL
The Lothian Regional Medical Ethics Committee approved the collection of human CL. These were collected with consent at the time of surgery from women with a regular menstrual cycle undergoing hysterectomy for benign conditions, as described previously (Duncan et al., 1996) . The CL was enucleated from the ovary by blunt dissection and the ovary was oversewn. Tissue was equally divided and half was fixed in 4% paraformaldehyde and processed into paraffin wax for immunohistochemistry and half was snap frozen in liquid nitrogen for molecular analyses.
CL were dated on the basis of the urinary luteinizing hormone LH surge and classified as early luteal (EL) [LH + 1 (representing 1 day after the detection of the urinary LH surge) to LH + 5; n ¼ 6], mid-luteal (ML) (LH + 6 to LH + 10; n ¼ 8) or late luteal (LL) (LH + 11 to LH + 14; n ¼ 8), and in all these cases the staging was consistent with the histology of an endometrial biopsy as described previously (Duncan et al., 1996) . Messenger RNA was also available from a bank of rescued CL (n ¼ 5) collected as described previously (Duncan et al., 1996) . Briefly, women received daily injections of hCG from LH + 7 in daily doubling doses, starting at 125 IU, for 5 -8 days until surgery. This treatment mimics the hormonal changes of early pregnancy and prevents luteolysis (Duncan, 2000) .
Collection of LGCs
The Lothian Regional Medical Ethics Committee separately approved the collection of LGCs from patients undergoing assisted conception.
LGCs were collected from women undergoing transvaginal oocyte retrieval following ovarian stimulation as described previously (Duncan et al., 2005a) . Follicular fluid was pooled and LGCs from two to four women were combined in each experiment.
A count of 100 000 viable cells were plated onto each well of 24-well plates precoated with Matrigel and cultured using 1 ml culture medium (Dulbecco's minimum essential medium/F12 Ham mixture containing 2 nM L-glutamine, 6.25 mg/l insulin, 6.25 mg/l transferrin, 6.25 mg/l selenious acid, 10 U/ml penicillin, 0.1 mg/ml streptomycin and 2.5 mg/ml amphoteracin B) at 378C in 5% CO 2 in air as described previously (Duncan et al., 2005a) .
Culture and treatment of LGCs
Media were refreshed every 2 -3 days over the course of the culture period for 6 days. On Day 7, three separate experimental paradigms were carried on at least three separate occasions: (i) 100 ng/ml hCG was added and cells were collected 2, 4, 8 and 24 h later (n ¼ 3), (ii) 100 ng/ml hCG was added and cells were collected 24 h later (n ¼ 6); and (iii) 50 ng/ml BMP2, BMP4, BMP6 or activin A (Myers et al., 2007; Hogg et al., 2010) , with or without 100 ng/ml hCG, was added and the cells were collected 24 h later (n ¼ 3 -6). In a separate experiment, the media were supplemented with 50 mg/l low-density lipoproteins, as a substrate to maintain normal progesterone synthesis over more prolonged cultures, with or without 10 ng/ml hCG from culture Day 1, and the cells were collected on Day 7 (n ¼ 3).
Preparation of cDNA from CL and LGC cultures CL and LGC mRNA was extracted using RNeasy mini-spin columns after lysis by the addition of RNeasy lysis buffer (Qiagen, West Sussex, UK) as described previously (Myers et al., 2007) . The protocol included on-column DNaseI digestion (Qiagen). Thereafter, mRNA concentrations were quantified using a NanoDrop ND-1000 Spectrophometer (NanoDrop Technologies, Wilmington, DE, USA) and mRNA was reverse transcribed into cDNA using random hexamers and a high-capacity kit (Applied Biosystems, Foster City, CA, USA) and subsequently stored at 2208C.
Polymerase chain reaction
ID1 -4 were PCR amplified from cDNA using specific primers (Table I) and visualized as described previously (Dickinson et al., 2008) . The reaction consisted of a denaturing step (958C for 5 min), and an annealing and extension step (958C for 15 s, 608C for 1 min) repeated 35 times, and a dissociation step (958C for 30 s, 608C for 45 s and 758C for 45 s) with a final step at 728C for 10 min. In addition to CL and LGCs, cDNA from human luteal fibroblast cells (Duncan et al., 2005b) were studied, and fetal brain and kidney were used as control tissues.
Quantitative real-time RT-PCR
The relative expression levels of genes of interest after treating the LGCs were measured by quantitative (q) RT -PCR as described previously . Primers (Table I) were prevalidated using conventional PCR and product sequencing and the efficiency was tested by generating standard curves in qRT -PCR. A 10 ml final reaction volume was used. Each sample contained 5.0 ml 2×PowerSYBRw Green PCR Master Mix (Applied Biosystems), 0.5 ml primer pair (5 mM), 3.5 ml nuclease free ID1 -4 in the corpus luteum H 2 O and 1 ml cDNA and each reaction was duplicate. The qRT -PCR cycling program consisted of a denaturing step (958C for 10 min), an annealing and extension step (95 for 15 s, 60 for 1 min) repeated for 40 cycles, and a dissociation step (95, 60 and 958C for 15 s each). The reactions were carried out in 384-well plates using 7900HT Sequence Detection System (Applied Biosystems). Each reaction was carried out in duplicate. Negative controls included reactions using cDNA prepared by omitting reverse transcriptase and a reaction substituting cDNA with nuclease-free water.
Analysis of gene expression
The relative expression level of each target gene to the stably expressed G6PDH house-keeping gene in luteal cells was quantified using the DDCt method, and statistical analysis was performed using a one-way analysis of variance with Bonferroni pairwise comparison or t-test where the samples were normally distributed. Otherwise non-parametric KruskalWallis with Dunn pairwise comparisons or Mann -Whitney testing were used. Values of P , 0.05 were regarded significant.
Immunohistochemistry
Tissue sections of 5 mm thickness were dewaxed and rehydrated through an alcohol series before undergoing antigen retrieval by pressure-cooking in 0.01 M sodium citrate buffer (pH 6.0) for 5 min. Sections were washed in phosphate-buffered saline (PBS), immersed in 3% H 2 O 2 for 10 min and blocked using avidin and biotin blocks for 15 min each, and then normal goat serum (NGS, Diagnostics Scotland, Edinburgh, UK) diluted 1:4 in PBS containing 5% (w/v) bovine serum albumin for 1 h at room temperature. These tissue sections were incubated overnight at 48C with primary antibodies (Table II) , then washed with PBS plus 1% Tween (PBST) before incubation with a biotinylated goat anti-rabbit IgG secondary antibody (Dako, Glostrup, Denmark) at a 1:500 dilution.
After additional washes in PBS, tissue sections were incubated with Vectastain ABC Elite tertiary complex (PK-1600 series; Vector Laboratories, Peterborough, Cambridgeshire, UK) for 1 h and bound antibodies were visualized by incubation with 3,3 ′ -diaminobenzidine (ImmPact DAB, Vector laboratories) for 30 s. Tissues were rinsed in distilled water, dehydrated in alcohol, counterstained with haematoxylin and mounted with pertex. For negative controls, primary antibodies were used at the same concentration but were incubated with blocking peptide (BP: 2 mg to 1 ml antibody) before application. Photomicrographs were taken using an Olympus Provis AX70 microscope (Olympus America Inc., Center Valley, PA, USA) equipped with a Zeiss AxioCam HRc camera (Carl Zeiss) and processed on Axiovision (Release 4.8.2, Carl Zeiss Inc.) and Adobe Photoshop CS5 Extended version 12.0 (Adobe) software.
Dual immunofluorescence
Tissue sections were treated in the same way as above for immunohistochemistry but with the following alterations to the protocol. After incubation with the appropriate secondary antibody (Table II) and subsequent washes in PBST, the appropriate tertiary complexes were applied and incubated for 1 h if streptavidin was applied and for 10 min if the TSA detection system was used (Table II) . Sections were subsequently subjected to antigen retrieval by microwaving for 2.5 min in 0.01 M sodium citrate buffer pH6.0. Sections were then washed in PBST and blocked in NGS as described previously. After an overnight incubation (48C) with the appropriate second primary antibody (Table II) , sections were washed and the appropriate secondary antibodies and tertiary complexes were added (Table II) 
Analysis of immunostaining
The different cell types were identified by morphological assessment (Duncan, 2000) . The overall intensity of positive staining in different cell types was assessed by three observers (blinded to the tissue identity) according to a four-point grading system: absent (0), low (1), moderate (2) and intense (3). The average score for each section was analysed using a Kruskal-Wallis test.
Results
ID genes are differentially expressed in the human CL
The expression of ID1-4 genes in human CL was confirmed by RT -PCR (Fig. 1a) . In order to assess any differential regulation, their expression was quantified across the luteal phase (Fig. 1b-e) . The expression of both ID1 (P , 0.05) and ID3 (P , 0.05) changed across the luteal phase with the highest expression in the LL stage ( Fig. 1b  and d ). Global expression of ID2 and ID4 did not change over the luteal phase ( Fig. 1c and e) . However, RT -PCR from different luteal cell types suggested that there may be stage-specific differential expression due to disparate cell types, which was particularly notable for ID4 (Fig. 1a) . We therefore localized ID1-4 in human CL across the luteal phase using immunohistochemistry.
Localization of ID1 -4 across the luteal phase in human CL Nuclear ID1 immunostaining in the steroidogenic granulosa-lutein and theca-lutein cells was largely absent in the EL and ML stages ( Fig. 2a  and b) although it seemed to be present in the LL stage (Fig. 2c) . Staining of the endothelial cells within the steroidogenic cell layer was present across the luteal phase but more notable in the EL and ML stages ( Fig. 2a and b) . In contrast, nuclear ID2 immunostaining in the steroidogenic cells seemed to be more marked in the EL and ML (Fig. 2d and e) stages than in the LL stage (Fig. 2f) . Patchy endothelial cell ID2 immunostaining could be detected throughout the stages of the luteal phase without any clear stage-specific pattern (Fig. 2d-f) .
This was not the case for ID3 (Fig. 2g -i ) and ID4 ( Fig. 2j-l) . For both of these proteins, there was endothelial cell immunostaining in the EL stage that seemed less marked in the LL stage. Nuclear immunostaining for ID3 (Fig. 2g -i ) in granulosa-lutein cells and theca-lutein cells could be detected across the luteal phase. Steroidogenic cell ID4 immunostaining was less marked but also seemed consistent across the luteal phase (Fig. 2j-l) .
ID3 and ID4 localization to endothelial cells during angiogenesis
In order to further study endothelial ID3 and ID4 across the luteal phase, these proteins were co-localized with an endothelial cell marker (CD31) in human CL tissue sections ( Fig. 3a and b) . Nuclear ID3 (Fig. 3a) and ID4 (Fig. 3b) immunostaining was confirmed in endothelial cells. Semi-quantitative scoring of endothelial cell staining intensity across the luteal phase suggested a reduction in ID3 (P ¼ 0.05) and confirmed a reduction in ID4 (P , 0.05). This is consistent with more endothelial cell ID3 and ID4 protein expression at the time of luteal angiogenesis.
Regulation of ID expression in luteal steroidogenic cells by hCG
We used cultures of human LGCs to investigate the effect of hCG on the regulation of ID1-4 gene expression (Fig. 4) . We found that acute or chronic administration of hCG did not significantly regulate ID1 in vitro or in vivo (Fig. 4a -d) .
ID2 and ID4 showed a similar regulation by hCG. Both acute ( Fig. 4f  and n) and chronic ( Fig. 4g and o) treatment with hCG in vitro increased their expression and this was evident within 2 h (Fig. 4e and m) of exposure (P , 0.05). Administration of hCG in vivo, however, did not regulate global expression of ID2 or ID4 in the CL (Fig. 4h and p) .
In contrast, expression of ID3 in the CL in vivo (Fig. 4l ) was inhibited by hCG (P , 0.01). Both acute (P , 0.001) and chronic (P , 0.01) treatment with hCG in vitro also inhibited ID3 expression ( Fig. 4j and k) although this effect was not fully evident until 8 h (Fig. 4i ) of exposure (P , 0.05). These results suggest differential regulation of the ID genes by hCG.
Differential regulation of ID expression by BMPs
In order to further assess the differential regulation of the ID1-4 in luteal steroidogenic cells, we assessed the effect of the BMPs and activin A and their interaction with hCG in vitro (Fig. 5) . Activin A had no significant effect on the expression of any of the ID genes. However, hCG and BMP treatment revealed a differential pattern of regulation for each of the ID genes (Fig. 5) . ID1 was not regulated by hCG but was generally increased by BMPs (P , 0.01 to P , 0.001; Fig. 5a ). In contrast, ID4 was increased by hCG (P , 0.01 to P , 0.001) and was not regulated by BMPs (Fig. 5d) . ID2 was generally increased by both hCG (P , 0.001) and BMPs (P , 0.05) and the effect was generally additive (P , 0.05 to P , 0.01; Fig. 5b ), while ID3 was increased by BMPs (P , 0.05 to P , 0.01) but reduced by hCG (P , 0.05) and, in combination their effects were cancelled out (Fig. 5c) .
Discussion
This is the first study to our knowledge to investigate the expression, localization and regulation of the ID genes in the CL. We show differentially regulated expression, in different luteal cell types, across the luteal phase. This suggests that IDs are likely to be involved in the transcriptional regulation involved in the dynamic cellular functional and structural changes during the lifespan of the CL. Although an increasing amount of information is becoming available about the mechanisms of luteinization, CL formation and luteolysis ), we do not yet fully understand the regulation of these processes at the molecular and cellular levels. This study provides new evidence that IDs may have roles in physiological tissue and vascular remodelling at a molecular and cellular level in the adult ovary.
ID1 -4 in the corpus luteum
This is perhaps not surprising as there are many precedents of genes with key roles in development, which are found to be dysregulated in cancer tissues, which are also found to be key, and tightly controlled, facilitators of physiological tissue remodelling in the adult ovary. For example, molecules with roles in the regulation of CL structure and function such as activin A (Myers et al., 2007) , matrix metalloproteinases (Duncan et al., 1998b) and the slit -robo interaction (Dickinson et al., 2008) have major developmental roles (Lemaître and D'Armiento, 2006; Xia and Schneyer, 2009; Dickinson and Duncan, 2010) and are dysregulated in cancer (Robertson et al., 2004; Dallol et al., 2005; Fridman, 2006; Dickinson et al., 2011) . IDs are key cellular regulators that are differentially expressed in multiple cell types during development in many species (Benezra et al., 1990) and also dysregulated in cancer cells (Lasorella et al., 2001; Ren et al., 2012) . Owing to these cell growth and differentiation functions, IDs (Norton, 2000) are plausible physiological regulators of the CL.
The IDs have previously been shown to be expressed in the ovaries of chickens (Johnson et al., 2008) , rats (Hennebold, 2004 ) and sheep (Hogg et al., 2010) where they may have roles in steroidogenic cell differentiation and function. It is well established that both activin (Telfer et al., 2008; Knight et al., 2012) and various BMPs (Knight and Glister, 2006; Campbell, 2009 ) have roles in the regulation of follicular growth and granulosa cell development. As IDs are important transcriptional regulators that are targeted by both activin and BMPs (Korchynskyi and ten Dijke, 2002; Hogg et al., 2010) , a role for them in ovarian follicular development is likely (Pangas, 2012) . Both activin and various Figure 2 Localization of ID1-4 in human CL across the luteal phase: ID1 in representative EL (a), ML with a negative control inset (b) and LL CL (c). ID2 in representative EL (d), ML with a negative control inset (e) and LL CL (f). ID3 in representative EL (g), ML with a negative control inset (h) and LL CL (i). ID4 in representative EL (j), ML with a negative control inset (k) and LL CL (l). White arrows point to granulosa-lutein cell nuclei and the black arrow highlights endothelial cells. Scale bars represent 100 mm.
BMPs are expressed in the CL (Shimasaki et al., 2004; Myers et al., 2007) and it is likely that they have important roles in the paracrine regulation of luteal structure and function. The regulation of ID expression seems to be part of these roles.
ID expression generally promotes cell growth and inhibits differentiation and lineage commitment. We suspected that ID expression may therefore be linked with CL formation and that ID expression would be highest in the EL phase (Duncan, 2000) . There was no evidence of increased ID1 -4 expression in the EL phase. Where statistical differences existed (with ID1 and ID3), the expression was maximal in the LL phase when luteolysis has started. However, immunohistochemistry suggested a possible role for some IDs in CL formation. Endothelial ID3 and ID4 immunostaining was most obvious during luteal formation that is the time of marked angiogenesis (Wulff et al., 2001; Fraser and Duncan, 2009 ). This suggests that ID expression may be involved in the regulation of endothelial cell growth and development.
There is existing evidence for a role of IDs in the promotion of angiogenesis. One role involves a paracrine, rather than direct, endothelial regulation, for example, over-expression of ID1 in cancer cells promotes angiogenesis (Ling et al., 2005) . Another would be a direct endothelial cell role as, for example, increasing ID1 expression in human umbilical vein endothelial (HUVEC) cells promotes their angiogenic capacity (Nishiyama et al., 2005) . ID3 expression has also been shown to have a role in the promotion of angiogenesis (Lyden et al., 1999) . It is likely that there is a direct endothelial cell component as Id3 knock-out mice could not vascularize tumour xenografts (Lyden et al., 1999) . While ID4 has a major role in neural proliferation and differentiation (Yun et al., 2004; Zeng et al., 2010) , it has also been shown to indirectly promote angiogenesis (Fontemaggi et al., 2009; Kuzontkoski et al., 2010) . Although its expression is mainly neuronal (Benezra et al., 2001) and it is not generally expressed in endothelial cells (Zeng et al., 2010) , we report its expression in endothelial cells suggesting that there may be a direct link to angiogenesis. Overall, ID1 -4 in the corpus luteum however, IDs interact with bHLH transcription factors, and bHLH proteins, perhaps such as E2-2 (Tanaka et al., 2010) , may be important in the direct regulation of angiogenesis.
If the involvement of steroidogenic cell ID expression is mainly in the regulation of luteolysis, rather than CL formation, it would be expected that expression would be highest in the LL phase and reduced by hCG in vivo (Duncan, 2000) . This is certainly the case with regards to ID3. In addition in vitro ID3 expression in luteinized granulosa was down-regulated by hCG in acute and chronic culture. While ID3 might promote angiogenesis in the EL phase its expression may contribute to steroidogenic cell regression in the LL phase. ID3 has been shown to promote cell apoptosis (Simbulan-Rosenthal et al., 2006; Li et al., 2012) and it is likely that it has such a role in granulosa-lutein cells during luteal regression.
Interestingly, the same is not the case for ID2 and ID4. Although not altered across the luteal phase or by hCG in vivo, ID2 and ID4 are rapidly up-regulated by hCG in vitro. Although TGF-b inhibition of Id2 (Cao et al., 2009) or phospho-ablation of Id2 (Butler et al., 2009) can induce apoptosis, other authors have found that Id2 can promote apotosis (Gleichmann et al., 2002) . Likewise some authors have demonstrated pro-apoptotic (Andres-Barquin et al., 1999) and anti-apoptotic (Ren et al., 2012) roles for ID4. It is therefore likely that the role of the IDs is context specific. In the human CL, ID2 and ID4 expression may be primarily luteotrophic while ID3 is primarily luteolytic.
The differential pattern of hCG regulation of expression between ID3 and ID2/ID4 is of particular interest. In the rat CL, these genes were identified by transcriptome analysis (Hennebold, 2004) . Interestingly Id1, Id2 and Id3 were associated through promotion by prolactin (luteotrophic) and inhibition by prostaglandin F 2a (luteolytic) (Hennebold, 2004) . Although Id2 and Id3 have been generally described to have similar expression and effects (Spits et al., 2000; Peddada et al., 2006; Heining et al., 2011) , differential expression has been previously implied (Simbulan-Rosenthal et al., 2006) . However, the differential regulation by hCG in human LGCs is probably the clearest illustration of their differential regulation.
It is likely that hCG can directly regulate ID expression in LGCs, particularly as the effect is rapid. However, there are other paracrine factors that are also likely to regulate their expression in luteal cells. Although activin A has clear effects in the regulation of LGC and luteal fibroblast (Myers et al., 2007) function and it decreases ID1 and ID3 expression in unluteinized ovine granulosa cells (Hogg et al., 2010) , it had little effect on ID expression in human LGCs. This was not the case for the BMPs. BMPs also have a role in the regulation of the CL (Knight and Glister, 2006; Kayani et al., 2009) and are known key regulators of ID expression Figure 5 The effect of BMPs and activin A and their combination with hCG on ID1 -4 expression in LGCs in vitro: the effect on hCG (100 ng/ml), BMP2 (50 mg/ml), BMP4 (50 ng/ml), BMP6 (50 ng/ml), activin A (50 ng/ml) and BMP2/hCG, BMP4/hCG, BMP6/hCG and activin A/hCG combinations on the relative expression of ID1 (a), ID2 (b), ID3 (c) and ID4 (d) in LGCs after 24 h culture. Data are mean + SEM. *P , 0.05, **P , 0.01, ***P , 0.001 and n.s is non-significant.
(ten Dijke et al., 2003) . Luteal BMPs are therefore also candidates for the local regulation of ID expression.
A combination of the effects of BMPs and hCG on LGC ID expression revealed a further distinction in the regulation of the various IDs. Indeed each of the IDs were differentially regulated in a different way. ID1 expression was not regulated by hCG but was up-regulated by BMPs. BMP regulation of ID1 is well described (ten Dijke et al., 2003) . In contrast, while ID4 was not regulated by BMPs, which has been described in other cellular systems (Tokuzawa et al., 2010) , its expression was up-regulated by hCG. ID2 was increased by both BMP and hCG, at maximally stimulating concentrations (Duncan et al., 2005a) , with an additive effect, suggesting different mechanisms of up-regulation. Again BMP regulation of ID2 is described in granulosa cells (Hogg et al., 2010) and other tissue systems (Lorda-Diez et al., 2009; Nakahiro et al., 2010) . Although, as expected (Kowanetz et al., 2004) , ID3 was up-regulated by BMPs, it was inhibited by hCG further suggesting different molecular pathways involved in the regulation of ID expression. It is clear that transcriptional regulation of ID expression is complex, tissue specific, and each ID has subtly different regulation of their expression in the same cell type.
In summary, specifically we have provided some evidence supporting involvement of the ID genes in the regulation of luteal structure and function in women. More generally, we have suggested a role for endothelial ID expression in tightly regulated physiological angiogenesis in adult tissues. In addition, we have shown that in one cell type there were regulatory pathways that could differentially regulate each of the ID genes. This highlights the complexity of these genes and the specific pathways involved in their regulation.
